| New therapeutic targets in soft tissue sarcoma. | |
| | |
MedLine Citation:
|
PMID: 22498582 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Soft tissue sarcomas are an uncommon and diverse group of more than 50 mesenchymal malignancies. The pathogenesis of many of these is poorly understood, but others have begun to reveal the secrets of their underlying mechanisms. With considerable effort over recent years, soft tissue sarcomas have increasingly been classified on the basis of underlying molecular alterations. In turn, this has allowed the development and application of targeted agents in several specific, molecularly defined, sarcoma subtypes. This review will focus on the rationale for targeted therapy in sarcoma, with emphasis on the relevance of specific molecular factors and pathways in both translocation-associated sarcomas and in genetically complex tumors. In addition, we will address some of the early successes in sarcoma-targeted therapy as well as a few challenges and disappointments in this field. Finally, we will discuss several possible opportunities represented by poorly understood, but potentially promising new therapeutic targets, as well as several novel biological agents currently in preclinical and early phase I/II trials. This will provide the reader with the context for understanding the current state of this field and a sense of where it may be headed in the coming years. |
| | |
Authors:
|
Elizabeth G Demicco; Robert G Maki; Dina C Lev; Alexander J Lazar |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Advances in anatomic pathology Volume: 19 ISSN: 1533-4031 ISO Abbreviation: Adv Anat Pathol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-13 Completed Date: 2012-08-06 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 9435676 Medline TA: Adv Anat Pathol Country: United States |
Other Details:
|
Languages: eng Pagination: 170-80 Citation Subset: IM |
Affiliation:
|
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030-4009, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use Apoptosis / genetics Autophagy Cell Proliferation / drug effects Clinical Trials as Topic Gastrointestinal Neoplasms / drug therapy, therapy Gastrointestinal Stromal Tumors / drug therapy Humans Molecular Targeted Therapy Oncogene Fusion Oncogene Proteins, Fusion / antagonists & inhibitors Sarcoma / drug therapy*, genetics, pathology, surgery Soft Tissue Neoplasms / drug therapy*, genetics, pathology Translocation, Genetic Tumor Suppressor Protein p53 / genetics |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA138345/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Oncogene Proteins, Fusion; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thyroid fine needle aspirate: a post-bethesda update.
Next Document: Hashimoto thyroiditis: a century later.